MedTrace Logo

A Phase II Study of HY209 Gel for Atopic Dermatitis Patients (Shaperon)

NCT04530643 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2022-01-28

No results posted yet for this study

Summary

A Randomized, Double-blinded, Placebo-controlled, Parallel, Multi-Center Phase II Clinical Study to Evaluate the Efficacy and Safety of HY209 gel for Patients with Atopic Dermatitis

Conditions

Interventions

DRUG

HY209 0.3%

25 subjects will be assigned to drug (HY209 0.3% gel).

DRUG

HY209 0.5%

25 subjects will be assigned to drug (HY209 0.5% gel).

DRUG

Placebo

25 subjects will be assigned to drug (Placebo).

Sponsors & Collaborators

  • Shaperon

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-26
Primary Completion
2021-09-07
Completion
2021-09-07

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04530643 on ClinicalTrials.gov